An international approach to the treatment of Hodgkin's disease in the elderly: Launch of the SHIELD study programme

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 63-67

  Proctor, Stephen J ^a   White, Jo ^b   Jones, Gail L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Elderly; Hodgkin's Lymphoma; Population based; Treatment Comorbidity

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MITOXANTRONE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

AGE; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONFERENCE PAPER; DISEASE SEVERITY; ELDERLY CARE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT PLANNING; ARTICLE; FACTUAL DATABASE; INTERNATIONAL COOPERATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; STANDARD;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; FEMALE; HODGKIN DISEASE; HUMANS; INTERNATIONAL AGENCIES; MALE; NEOPLASM STAGING;

EID: 84900436030     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. PROCTOR SJ, RUEFFER JU, ANGUS B, et al. Hodgkin's disease in the elderly: current status and future directions. Ann Oncol 2002;13:133-137.
2. PETERSON BA, PAJAK TF, COOPER MR, et al. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 1982;66:889-898.
3. WEDELIN C, BJORKHOLM M, BIBERFIELD P, et al. Prognostic factors in Hodgkin's disease with special reference to age. Cancer 1984;53:1202-1208.
4. EGHBALI H, HOERNI-SIMON G, DE MASCAREL I, et al. Hodgkin's disease in the elderly. A series of 30 patients aged older than 70 years. Cancer 1984;53:2191-2193.
5. SPECHT L, NISSEN NI. Hodgkin's disease and age. Eur J Haematol 1989;43:127-135.
6. VAN SPRONSEN DJ, JANSSEN-HEIJNEN ML, BREED WP, COEBERGH JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma. Ann Haematol 1999;78:315-319.
7. MONFARDINI S, FERRUCCI L, FRATINO L, et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1995;77:395-401.
8. EXTERMANN M, OVERCASH J, LYMAN GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-1587.
9. EXTERMANN M, CHEN H, CANTOR AB, et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer 2002;38:1466-1473.
10. LEVIS A, ANSELMO AP, AMBROSETTI A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results for an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004;15:123-128.
11. Office of Population Censuses and Surveys. Population projections by the government actuary. HMSO 1991.
12. General Register Office for Scotland. Scotland's Census 29 April 2001. http://www.scrol.gov.uk: 2004.
13. McELWAIN TJ, TOY J, SMITH EP, et al. Combination chemotherapy of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer 1977;36:276-280.
14. CANELLOS GP, ANDERSON JR, PROPERT KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
15. STARK GL, WOOD KM, JACK F, et al. Hodgkin's disease in the elderly: a population-based study. Br J Haematol 2002;119:432-440.
16. Ann Arbor Staging System. Symposium sponsored by the American Cancer Society and the National Cancer Institute, Ann Arbor, Michegan. Cancer Res 1971;31:1707-1861.
17. GUINEE VF, GIACCO GG, DURAND M, et al. The prognosis of Hodgkin's disease in older adults. J Clin Oncol 1991;9:947-953.
18. ERDKAMP FL, BREED WP, BOSCH LJ, et al. Hodgkin's disease in the elderly, a registry-based analysis. Cancer 1992;7:830-834.
19. ENBLAD G, GUSTAVSSON A, SUNDSTROM C, GLIMELIUS B. Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. Acta Oncol 2002;41:659-667.
20. LEVIS A, DEPAOLI L, BERTINI M, et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 1996;81:450-456.
21. ZINZANI PL, MAGAGNALI M, BENDANDI M, et al. Efficacy of VBM regimen in the treatment of elderly patients with Hodgkin's disease. Haematologica 2000;85:729-732.
22. BALLOVA V, RUFFER JU, HAVERKAMP H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol 2005;16:124-131.
23. MACPHERSON N, KLASA RJ, GASCOYNE, R et al. Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma 2002;43:1395-1402.
24. WEEKES CD, VOSE JM, LYNCH JC, et al. Hodgkin's disease in the elderly: improved treatment outcomes with a doxorubicin-containing regimen. J Clin Oncol 2002;20:1087-1093.
25. LENNARD AL, CAREY PJ, JACKSON GH, PROCTOR SJ. An effective oral combination in advanced relapsed Hodgkin's disease: prednisolone, etoposide, chlorambucil and CCNU. Cancer Chemother Pharmacol 1990;26:301-305.
26. BRUSAMOLINO E, CASTELLI G, PAGNUCCO G, et al. CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease. Haematologica. 1990;75:340-345.
27. BRUSAMOLINO E, ORLANDI E, CANEVARI A, et al. Results of CAV regimen (CCNU, melphaln and VP-16) as third-line salvage for Hodgkin's disease. Ann Oncol 1994;5:427-432.